Keywords
MONOCLONAL ANTIBODY
TARGETED DRUG DELIVERY
CANCER THERAPY
How to Cite
Abstract
Monoclonal antibody (MAB) conjugates with cytostatic agents (ADC) are intended for selective delivery of a cytostatic agent to a tumor cell. Three ADC have been approved for clinical use (gemtuzumab ozogamicin, brentuximab vedotin, trastuzumab-DM1); a few dozens of other ADC are undergoing clinical trials. Several derivatives of natural substances (antibiotics and inhibitors of microtubules) having a high antitumor activity are used as cytostatic agents included in ADC. They are inapplicable in clinical practice as self-sustained drugs due to their considerable toxicity. Of great importance for the implementation of the ADC effect is the character of a linker connecting MAB with a cytostatic agent and ensuring selective intracellular release after ADC internalization. The structure, mechanisms of action, and the results of clinical trials of a number of ADC are considered here as an illustration (by way of example). The development of ADC can help introduce new effective cytostatic agents into clinical practice.References
Lampert J.M., Morris C.Q. Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review // Adv. Ther. - 2017. - Vol. 34. - № 5. - P. 1015-1035. -. DOI: 10.1007/s1225-017-0519-6
Trail P.A., Dubowchik M., Lowinger T.B. Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design // Pharmacol. Therapeutics. - 2018. - Vol. 181. - № 11. - P. 126-142. - DOI: 10.1016/j.spharmthera.2017.-07-013
Beck A., Peichewrt J.M. Antibody-drug conjugates // mABS. - 2014. - Vol. 6. - № 1. - P. 15-17. - DOI: 10.4161/mabs.27436
Jerjian T.V., Glode A.E., Thompson J.A., O'Bryant C.L. Antibody-drug conjugates: a clinical pharmacology perspective on an emerging cancer therapy // Pharmacotherapy. - 2016. - VoL. 36. - № 1. - P. 99-116. -. DOI: 10.1002/phar.1687
Sau S., Stlsaab H.O., Kashaw S.K., Tatiparti K., Lyer A.K. Advances in antibody-drug conjugates: a new era of targeted cancer therapy // Drug Discov.Today. - 2017. -Vol. 22. - № 10. - P. 1547-1556. - DOI: 10.1016/j.drugs.2017.05.011
Hamelton G.S. Antibody-drug conjugates for cancer therapy: the technological and regulatory challenges of developing drug-biologic hybrids // Biologicals. - 2015. -Vol. 43. - № 5. - P. 318-332. - DOI: 10.1016/j. Biologicals.2015.05.006.
Diamantis N., Bnerji U. Antibody-drug conjugates -an emerging class of cancer treatment // Brit. J. Cancer. - 2016. - Vol. 114. - P. 362-367. - DOI: 10.1038/bjc.2015.435
Thomas A., Teicher B.A., Hassan R. Antibody-drug conjugates for cancer therapy // Lancet Oncol. - 2016. - Vol. 17. - № 6. - P. 254-262. - DOI: 10.1016/s1470-2045(16)30030-4
Bouchard H., Viskov C., Garcia-Echeverria C. Antibodydrug conjugates - a new wave of cancer therapy drugs // Bioorg. med. chem. lett. - 2014. - Vol. - № 23. - P. 5357-5363. - doi: 10.106/j. bmel.2014.10.021.
Корман Д.Б. Мишени и механизмы действия противоопухолевых препаратов. - Москва: Практическая медицина, 2015. - 333 с.
Walsra-Washer A., Robak T. Safety and tolerability of antibody-drug conjugates in cancer // Drug Safety. -2019. - Vol. 42. - № 2. - P. 295-314. - doi: 10/1007/ s40264-018-0775-7.
Stein E.M., Walter R.B., Erba H.R. et al. A phase I trial of vadatuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia // Blood. -2018. - Vol. 131. - № 4. - P. 387-396. - DOI: 10.1182/blood-2017-06-789800
Lashary B.H., Vallatharasu Y, Kolandra L., Hamid M., Uprety D. Rovalpituzumab teserine: a novel DLL3-targeting antibody-drug conjugate // Drugs RD. - 2018. - Vol. 18. - № 4. - P. 255-258. - DOI: 10.1007/s40268-018-0247-7.
Tanaka K., Isse K., Fujihira T. et al. Prevalence of delta-like protein 3 expression in patients with small cell Lung cancer // Lung cancer. - 2018. - Vol. 115. - № 1. - P. 116-120. - DOI: 10.1016/j.lungcan.2017-11-018.
Rudin C.M., Pietanza C., Bauer T.M. et al. Rovalpituzum-ab teserine, DLL3-targeted antibody-drug conjugate in reccurent small-cell lung cancer: a first-in-human, firstin class, open-label, phase I study // Lancet Oncol. - 2017. - Vol. 18. - № 1. - P. 42-51. - DOI: 10.1016/s1470-2045(16)30565-4
Roth M., Barris D.M., Piperdi S. et al. Targeting glycoprotein NMB with antibody-drug conjugate, glembatumab vedotin, for the treatment of osteosarcoma // Pediatr. Blood Cancer. - 2016. - Vol. 63. - № 1. - P. 32-38. - DOI: 10.1002/pbc.25688
Rose A.A., Biondim M., Curiel R., Sigel P.M. Targeting GPNMB with glembatumab vedotin: current development and future opportunities for the treatment of cancer // Pharmacology and Therapeutics. - 2017. - Vol. 179. - № 11. - P. 127-141. -. DOI: 10.1016/phar-mthera.2017.05.010
Ott P.A., Pavlick A.C., Johnson D.B. et al. A phase 2 study of glembatumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB in patients with advanced melanoma // Cancer. - 2019. - Vol. 125. - № 7. - P. 1113-1123. - DOI: 10.1002/cncr.31892
Pereira D.C., Guevaral I., Jin L. et al. AGS67E, an an-ti-CD37 monomethyl-auristatin E-antibody conjugate as a potential therapeutic for B/T-cell malignancies and AML: a new role for CD37 in AML // Mol. Cancer Ther. - 2015. - Vol. 14. - № 7. - P. 1650-1660. -. DOI: 10.1158/1535-7163.MCT-15-0067
Moore K.H., Martin L.P., O'Malley D.H. et al. A review of mirvetuximab sorvatansine in the treatment of platinum-resistant ovarian cancer // Future Oncol. - 2018. - Vol. - № 2. - P. 123-136. - DOI: 10.2217/fon-2017-0379
Golfier S., Kopitz C., Kahnert A. et al. Anentumab ravtansine: A novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect // Mol. Cancer Ther. - 2014. - Vol. 13. - № 6. - P. 1537-1548. -. DOI: 10.1156/1135-7163.MCT-13-0926
Quanz M., Hagemann U.B., Zitzmanh-Kolbe S. et al. Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin expressing ovarian cancer models // Oncotarget. - 2018. - Vol. 9. - P. 34103-34121. - DOI: 10.18632/oncotarget26135
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2019 David Korman